Pfizer Inc. announced positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment in people with moderately severe hemophilia B.
The National Hemophilia Foundation is undertaking a project to develop evidence-based clinical practice guidelines in hemophilia. The NHF will focus on evaluating different care models, including the comprehensive care model of the Hemophilia Treatment Centers with a goal to support patient-centered decision making and optimize hemophilia care for each patient. See full story at hemophilia.org
FDA Approves Longer-Lasting Drug Eloctate For Treatment of Hemophilia A
The Food and Drug Administration has approved Eloctate, a new long-acting drug by Biogen Idec Inc., for the treatment of hemophilia A. The approval comes just two months after the FDA approved Biogen Idec's hemophilia B treatment Alprolix. Full Story at bostonglobe.com
European Commission Approves Pradaxa for Prevention of DVT and PE
Boehringer Ingelheim announced that Pradaxa (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE). The U.S. FDA approved Pradaxa earlier this year. Full Story at news-medical.net
Drug Companies Pledge Factor VIII Donation in Developing Countries
Biogen Idec Inc. and their partner Swedish Orphan Biovitrum AB recently announced that they will donate one billion international units of Factor VIII therapy for humanitarian aid programs. Full Story at healio.com and informational video can be found at wn.com.
Dr. Tim Bernard in Denver Post Article about CU Grant & Research on Pediatric Stroke
The HTC's Dr. Tim Bernard was featured in a recent article in the Denver Post that highlighted the $2.5 million grant that will fund research that is now underway on the effects of strokes on children. Dr. Bernard is one of the experts on the research team studying pediatric stroke. Full Story at denverpost.com (photo: Kathryn Scott Osler, The Denver Post)
The HTC Has Also Joined Twitter! Follow Us and Get Involved!
The HTC has joined Twitter and created a profile here: https://twitter.com/HTCColorado
. Any of our patients, families, fellow providers and other interested parties are welcome to follow us and keep up with the latest news, events and information about our center and the disorders we treat.
See our Social Media page for more.
The HTC Has Joined Facebook. Like Our Page and Connect With Us Today!
The HTC has joined Facebook by creating a page here: https://www.facebook.com/ColoradoHTC If Facebook is a social media tool our patients and families use, we hope they will connect with us and keep up with the latest news, events and information about our center, hemophilia, bleeding and clotting disorders and pediatric stroke. See our Social Media page here.
New Findings in Study Support Less Frequent Dosing for Hemophilia B Patients
CSL Behring presented findings at the World Federation of Hemophilia 2014 that supported less frequent dosing in Hemophilia B patients treated with coagulation factor IX with recombinant Albumin (rIX-FP). The study is ongoing and changes in this treatment for Hemophilia B patients has not been approved in the United States. Full Story at pipelinereview.com
FDA Approves Kogenate FS for Adults with Hemophilia A
Bayer HealthCare announced that the U.S. Food and Drug Administration has approved a new indication for Bayer's Kogenate FS antihemophilic factor VIII (recombinant) based on data from a study headed by Marilyn Manco-Johnson, M.D. at the University of Colorado Hemophilia and Thrombosis Center at Anschutz Medical Campus. Full Story at marketwatch.com
Baxter Announces FDA Approval of ADVATE with BAXJECT III Reconstitution System
Baxter International announced on April 23, 2014 that the U.S. Food and Drug Administration has approved a new reconstitution system for ADVATE (Antihemophilic Factor [Recombinant]). ADVATE and the diluent come pre-packaged in the new BAXJECT III reconstitution system.
88% of Previous Relapsers Achieve Hepatitis C Cure with Simeprevir-based Triple Therapy
Almost 90% of European patients who had relapsed after previous treatment with pegylated interferon and ribavirin were cured of hepatitis C after 24 weeks of treatment with the protease inhibitor simeprevir combined with pegylated interferon and ribavirin, the 49th Annual Meeting of the European Association for the Study of the Liver heard on Thursday in London. Full story at aidsmap.com
Boehringer's Pradaxa gets FDA Approval for DVT, PE treatment
Germany-based pharmaceutical firm Boehringer Ingelheim has received approval from the U.S. Food and Drug Administration for Pradaxa to treat venous thromboembolism (VTE), which includes both deep venous thrombosis (DVT) and pulmonary embolism (PE). Full story at PBR
U.S. FDA Approves Biogen's Hemophilia B Drug Alprolix
Biogen Idec Inc. has won US. Approval for its long-acting hemophilia B treatment Alprolix. Canada approved the drug designed to extend the time between infusions for hemophiliacs who are missing factor IX proteins a week prior to the FDA approval. Full story at Reuters.com
Baxter Acquires Chatham for $70M+, Boosting Its Hemophilia Pipeline
Baxter, an American health care company with over 60 years experience in developing hemophilia products, has purchased Chatham, a private biotechnology company developing treatments for hemophilia.
Full story at GEN News and Chicago Tribune
Canada OKs Biogen Idec drug for treatment of hemophilia B
Canadian health officials have okayed a Biogen Idec Inc. drug that controls and prevents bleeding in patients with hemophilia B, marking the first approval of a new hemophilia treatment in nearly two decades and the entry of the Cambridge biotech into a market beyond multiple sclerosis medicines.
Stroke in children will be focus of $3 million grant at CU
Researchers at the University of Colorado Denver | Anschutz Medical Campus will receive a $3 million grant as part of a national effort to better understand stroke. The research, which will involve several researchers and doctors at the HTC, will be a collaboration with Children's Hospital Colorado, University of Colorado Hospital and the School of Medicine. Full story at Phys.org
New Hemophilia Drugs Aim to Simplify Treatment
For 33-year-old video editor and hemophilia patient Travis Roop, being able to get life-saving infusions of a blood clotting agent every two weeks, instead of rushing to treat a bleeding episode, meant he could jog for the first time.
Full Story at Reuters.com